|Trade names||Sprycel, Dasanix|
|By mouth (tablets)|
|Defined daily dose||not established|
|Elimination half-life||1.3 to 5 hours|
|Excretion||Fecal (85%), kidney (4%)|
|Chemical and physical data|
|Molar mass||488.01 g·mol−1|
|3D model (JSmol)|
Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.
Common side effects include low white blood cells, low blood platelets, anemia, swelling, rash, and diarrhea. Severe side effects may include bleeding, pulmonary edema, heart failure, and prolonged QT syndrome. Use during pregnancy may result in harm to the baby. It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.
Dasatinib was approved for medical use in the United States and in the European Union in 2006. It is on the World Health Organization's List of Essential Medicines. In the United Kingdom, as of 2021, the medication costs the NHS about £2,500 per month of treatment.
In the EU dasatinib is indicated for children with
- newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.
- newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.
- newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.
and adults with
- newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;
- chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;
- Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
The usual dosage for chronic myelogenous leukemia (chronic phase) is 100 mg orally once a day. A daily dose of 100 mg is also used for Philadelphia chromosome-positive acute lymphoblastic leukaemia. Oral absorption is not affected by food, and only 20% of unaltered dasatinib is found unaltered in faeces.The defined daily dose is not established
The most common side effects are infection, suppression of the bone marrow (decreasing numbers of blood cells), headache, hemorrhage (bleeding), pleural effusion (fluid around the lungs), dyspnea (difficulty breathing), diarrhea, vomiting, nausea (feeling sick), abdominal pain (belly ache), skin rash, musculoskeletal pain, tiredness, swelling in the legs and arms and in the face, fever.
Neutropenia and myelosuppression were common toxic effects. Fifteen people (of 84, i.e. 18%) in the above-mentioned study developed pleural effusions, which was a suspected side effect of dasatinib. Some of these people required thoracentesis or pleurodesis to treat the effusions. Other adverse events included mild to moderate diarrhea, peripheral edema, and headache. A small number of people developed abnormal liver function tests which returned to normal without dose adjustments. Mild hypocalcemia was also noted, but did not appear to cause any significant problems. Several cases of pulmonary arterial hypertension (PAH) were found in people treated with dasatinib.
On October 11, 2011, the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH). Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, people developed PAH after starting dasatinib, including after more than one year of treatment. Information about the risk was added to the Warnings and Precautions section of the Sprycel drug label.
Dasatinib is an ATP-competitive protein tyrosine kinase inhibitor. The main targets of dasatinib are BCR/Abl (the "Philadelphia chromosome"), Src, c-Kit, ephrin receptors, and several other tyrosine kinases.[medical citation needed]
Dasatinib was developed by collaboration of Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd, and named for Bristol-Myers Squibb research fellow Jagabandhu Das, whose program leader says that the drug would not have come into existence had he not challenged some of the medicinal chemists' underlying assumptions at a time when progress in the development of the molecule had stalled.
In October 2010, dasatinib was approved in the United States for the treatment of newly diagnosed adults with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (CP-CML).
In November 2017, dasatinib was approved in the United States for the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
Approval was based on data from 97 pediatric participants with chronic phase CML evaluated in two trials—a Phase I, open-label, non-randomized, dose-ranging trial and a Phase II, open-label, non-randomized trial. Fifty-one participants exclusively from the Phase II trial were newly diagnosed with chronic phase CML and 46 participants (17 from the Phase I trial and 29 from the Phase II trial) were resistant or intolerant to previous treatment with imatinib. The majority of participants were treated with dasatinib tablets 60 mg/m2 body surface area once daily. Participants were treated until disease progression or unacceptable toxicity.
The Union for Affordable Cancer Treatment objected to the price of dasatinib, in a letter to the U.S. trade representative. The average wholesale price in the U.S. is $367 per day, twice the price in other high income countries. The price in India, where the average annual per capita income is $1,570, and where most people pay out of pocket, is Rs6627 ($108) a day. Indian manufacturers offered to supply generic versions for $4 a day, but, under pressure from the U.S., the Indian Department of Industrial Policy and Promotion refused to issue a compulsory license.
Bristol-Myers Squibb justified the high prices of cancer drugs with the high R&D costs, but the Union of Affordable Cancer Treatment said that most of the R&D costs came from the U.S. government, including National Institutes of Health funded research and clinical trials, and a 50% tax credit. In England and Wales, the National Institute for Health and Care Excellence recommended against dasatinib because of the high cost-benefit ratio.
The Union for Affordable Cancer Treatment said that "the dasatinib dispute illustrates the shortcomings of US trade policy and its impact on cancer patients".
- "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 23 October 2020. Retrieved 11 September 2020.
- "Sprycel (Dasatinib)". TGA. Archived from the original on 19 July 2020. Retrieved 18 July 2020.
- "Dasatinib". The American Society of Health-System Pharmacists. Archived from the original on 10 December 2017. Retrieved 8 December 2017.
- "Sprycel EPAR". European Medicines Agency (EMA). Archived from the original on 22 May 2020. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "8. Immune system and malignant disease". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021. pp. 1027–1029. ISBN 978-0-85711-413-6.
- Keating GM (January 2017). "Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia". Drugs. 77 (1): 85–96. doi:10.1007/s40265-016-0677-x. PMID 28032244.
- "Dasatinib Dosage". Drugs.com. 31 December 2019. Archived from the original on 15 June 2020. Retrieved 15 June 2020.
- Levêque D, Becker G, Bilger K, Natarajan-Amé S (2020). "Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib". Clinical Pharmacokinetics. doi:10.1007/s40262-020-00872-4. PMID 32112275.
- "NHS - Healthcare News". nelm.nhs.uk. Archived from the original on 5 May 2013. Retrieved 27 September 2011.
- "Sprycel (dasatinib) and risk of pulmonary arterial hypertension". U.S. Food and Drug Administration (FDA). 23 September 2011. Archived from the original on 19 September 2020. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.
- Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, et al. (June 2006). "The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants". Cancer Research. 66 (11): 5790–7. doi:10.1158/0008-5472.CAN-05-4187. PMID 16740718.
- "Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area". Archived from the original on 28 March 2015. Retrieved 23 April 2015.
- "FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase". Bristol-Myers Squibb (Press release). Archived from the original on 20 September 2018. Retrieved 23 April 2015.
- "Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY and Establishment of an Oncology Collaboration with Otsuka". Bristol-Myers Squibb (Press release). Archived from the original on 20 September 2018. Retrieved 23 April 2015.
- Drahl, Carmen (16 January 2012). "How Jagabandhu Das made dasatinib possible". The Safety Zone blog. Chemical & Engineering News. Archived from the original on 10 December 2017. Retrieved 29 August 2016.
- "Drug Approval Package: Sprycel (Dasatinib) NDA #021986 & 022072". U.S. Food and Drug Administration (FDA). 6 September 2006. Archived from the original on 19 September 2020. Retrieved 28 April 2020.
- "2010 Notifications". U.S. Food and Drug Administration (FDA). 18 November 2010. Archived from the original on 28 April 2020. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.
- "FDA approves dasatinib for pediatric patients with CML". U.S. Food and Drug Administration (FDA). 9 November 2017. Archived from the original on 28 April 2020. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.
- Cohen D (November 2014). "US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says". BMJ. 349: g6593. doi:10.1136/bmj.g6593. PMID 25370846.
- Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. (December 2004). "Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays". Journal of Medicinal Chemistry. 47 (27): 6658–61. doi:10.1021/jm049486a. PMID 15615512.